AMPLIFY-201, a first-in-human safety and efficacy trial of adjuvant ELI-002 2P immunotherapy for patients with high-relapse risk with KRAS G12D- or G12R-mutated pancreatic and colorectal cancer Meeting Abstract
| Authors: | O'Reilly, E. M.; Wainberg, Z. A.; Weekes, C. D.; Furqan, M.; Kasi, P. M.; Devoe, C. E.; Leal, A. D.; Chung, V.; Perry, J.; Seenappa, L.; McNeil, L.; Welkowsky, E.; DeMuth, P.; Haqq, C. M.; Pant, S. |
| Abstract Title: | AMPLIFY-201, a first-in-human safety and efficacy trial of adjuvant ELI-002 2P immunotherapy for patients with high-relapse risk with KRAS G12D- or G12R-mutated pancreatic and colorectal cancer |
| Meeting Title: | 2023 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2023 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-06-01 |
| Language: | English |
| DOI: | 10.1200/JCO.2023.41.16_suppl.2528 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: 2528 -- This meeting was also held virtually -- Source: Cinahl |
